The Contact Energy Ltd (ASX: CEN) share price is on investors’ radar after the company posted higher electricity and gas sales for June 2026, along with ongoing progress on major renewable energy projects.

What did Contact Energy report?

• Mass market electricity and gas sales reached 495 GWh in June 2026, up from 410 GWh last year
• Contracted wholesale electricity sales totalled 1,056 GWh (June 2025: 810 GWh)
• Electricity and steam net revenue was $175.68/MWh, compared to $186.08/MWh in June 2025
• Electricity generated (or acquired) increased to 1,101 GWh (June 2025: 846 GWh)
• Unit generation cost, including acquired generation, dropped to $38.16/MWh from $54.27/MWh
• Retail netback decreased slightly, to $141.18/MWh from $146.32/MWh

What else do investors need to know?

Contact Energy is progressing with several renewable energy developments, including the Kōwhai Park Solar, Te Mihi Stage 2 geothermal, Glenbrook-Ohurua Battery 2, and Glorit Solar, with a combined approved cost of over $1.5 billion and staggered completion dates out to 2028.

Hydro storage levels were well above average as of mid-July 2026, with the South Island at 145% and the North Island at 123% of mean levels. The Clutha catchment saw strong inflows, supporting overall storage and generation options.

New Zealand’s electricity demand remained broadly steady, down 0.04% on June 2025, but up 1.1% versus June 2024, during what was the warmest June on record.

What’s next for Contact Energy?

Contact Energy is maintaining its focus on expanding renewable energy, reducing unit generation costs, and delivering reliable energy for customers. Upcoming project completions, especially in solar and battery storage, are poised to increase renewable supply in the next few years.

The company’s continued investments in sustainability, along with a healthy pipeline of projects, underline its commitment to low-carbon generation and growing market share in a stable demand environment.

Contact Energy share price snapshot

Over the past 12 months, Contact Energy shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

View Original Announcement

This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The post Contact Energy June 2026 earnings: Sales rise, renewables progress appeared first on The Motley Fool Australia.

More reading

• HUB24 earnings: Record $18.9bn net inflows lift FUA
• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• South32 reveals FY26 operating results

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company posted Q2 2026 group revenue of US$247 million, up 21% on the prior year, and reaffirmed its full-year revenue guidance.

What did Telix Pharmaceuticals report?

• Q2 2026 group revenue: US$247 million, up 21% year-over-year and 7% quarter-on-quarter
• Precision Medicine revenue: US$202 million, up 30% year-over-year and 9% quarter-on-quarter
• TMS revenue: US$45 million
• FY 2026 revenue and other income expected to exceed US$1 billion, tracking towards the upper end of guidance (US$950–970 million plus US$40 million Regeneron income)
• R&D expenditure guidance updated to US$230–270 million, reflecting increased investment capacity
• Initial non-refundable payment of US$40 million received from strategic partner Regeneron

What else do investors need to know?

Telix Pharmaceuticals continues to make progress across both its Precision Medicine and Therapeutics businesses. The company achieved a key regulatory milestone for the global Phase 3 trial of TLX591-Tx in prostate cancer, with FDA alignment allowing the study to advance to Part 2 in the US. Enrolment is ongoing in several regions, including Australia and China.

In its Precision Medicine business, Telix is nearing full patient enrolment in the BiPASS Phase 3 study for initial prostate cancer diagnosis, and has completed enrolling for its Phase 3 registrational study in Japan for Illuccix. The company is also progressing new regulatory filings and expanding its manufacturing footprint with new facilities in Melbourne, Brussels, and Yokohama.

Telix finalised a major strategic collaboration with Regeneron to develop radiopharmaceutical therapies, receiving an upfront payment and creating a strong platform for future oncology programs. The company also refinanced existing convertible bonds, boosting its capital flexibility.

What did Telix Pharmaceuticals management say?

Dr. Christian Behrenbruch, Managing Director and Group CEO, said:

We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value

What’s next for Telix Pharmaceuticals?

Looking ahead, Telix expects FY 2026 revenue and other income to top US$1 billion, and is allocating additional funds to R&D to support the expansion of key clinical programs. Progress in product development, regulatory filings, and the new Regeneron partnership are expected to underpin further growth.

Management flagged ongoing milestones for pivotal clinical trials in both the Therapeutics and Precision Medicine businesses, as well as continued global geographic expansion. The company’s strengthened capital position will support investment in its late-stage pipeline and manufacturing capability, with a focus on bringing new therapies to market.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: Q2 2026 revenue jumps 21% appeared first on The Motley Fool Australia.

More reading

• HUB24 earnings: Record $18.9bn net inflows lift FUA
• Top 3 ASX healthcare stocks to watch
• Contact Energy June 2026 earnings: Sales rise, renewables progress
• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The ASX dividend share Future Generation Australia Ltd (ASX: FGX) could be one of the best choices that Aussie retirees could make. It offers numerous benefits to investors focused on passive income, as well as people who want diversification.

Future Generation Australia is a name I’ve had in my portfolio for several years already and I plan to continue holding it for a few different reasons.

Let’s look at why it’s such a compelling reason for retirees to buy for the long-term.

Diversification

Future Generation Australia is a listed investment company (LIC) that is invested in the funds of fund managers like Paradice, L1 Group Ltd (ASX: L1G), Wilson Asset Management, Vinva, Eley Griffiths and so on.

All of those find managers work for free so that Future Generation Australia can donate 1% of its net assets each year to youth charities, including Giant Steps, Mirabel Foundation, Raise, Karinyahouse and Lighthouse.

By being invested in so many different fund managers, the ASX dividend share gives investors exposure to more than 430 businesses.

I think it really ticks the diversification box, while also giving more market capitalisation diversification.

Around 19% of the portfolio is invested in companies outside of the S&P/ASX 300 Index (ASX: XKO), showing that the LIC can give exposure to some of the smaller and more growth-orientated stocks in Australia – I think this is a key reason why Future Generation Australia’s portfolio has beaten the return of the S&P/ASX All Ordinaries Accumulation Index (ASX: XAOA) by an average of around 1% per year.

Large dividend yield

One of the main reasons to like this ASX dividend share is its strong dividend yield. There are few businesses that I’d be more willing to invest in for a large dividend yield than Future Generation Australia.

The business expects to pay an annual dividend per share for 2026 of 7.6 cents. At the time of writing, that translates into a grossed-up dividend yield of 8%, including franking credits.

In my view, that’s a far better yield than what term deposits and most other ASX blue-chip shares have to offer.

Growing payouts

Another reason for retirees to love this business is that it has regularly increased its annual dividend for investors. It has increased its annual payout each year since 2015, so 2026 is more than a decade of increases.

Dividend growth is not guaranteed, of course, but with Future Generation Australia’s impressive track record and profit reserve of 41.8 cents per share, I think it’s well positioned to continue growing dividends in the next few years.

Over the long-term, I think Future Generation Australia can continue to deliver rising payouts for retirees and other shareholders.

The post Why this ASX dividend share is a retiree’s dream for 2026 appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $100,000 annual passive income?
• How much superannuation is needed to target a $100,000 annual passive income?
• 2 ASX shares with dividend yields above 7.5%
• How much is needed in superannuation to target $60,000 in annual passive income?
• $1,000 buys 735 shares in an incredibly reliable ASX dividend stock

Motley Fool contributor Tristan Harrison has positions in Future Generation Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.